U.S. markets open in 4 hours 5 minutes
  • S&P Futures

    3,795.00
    -21.75 (-0.57%)
     
  • Dow Futures

    31,104.00
    -132.00 (-0.42%)
     
  • Nasdaq Futures

    12,604.50
    -77.25 (-0.61%)
     
  • Russell 2000 Futures

    2,186.50
    -19.30 (-0.87%)
     
  • Crude Oil

    60.78
    -0.50 (-0.82%)
     
  • Gold

    1,710.60
    -5.20 (-0.30%)
     
  • Silver

    25.99
    -0.40 (-1.50%)
     
  • EUR/USD

    1.2044
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.33
    +3.23 (+13.40%)
     
  • GBP/USD

    1.3929
    -0.0024 (-0.17%)
     
  • USD/JPY

    107.3300
    +0.3280 (+0.31%)
     
  • BTC-USD

    49,123.02
    -1,944.03 (-3.81%)
     
  • CMC Crypto 200

    985.55
    -1.66 (-0.17%)
     
  • FTSE 100

    6,609.23
    -66.24 (-0.99%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient

Elizabeth Balboa

Forward Pharma A/S (NASDAQ: FWP) plummeted 30 percent Friday on news of Biogen Inc (NASDAQ: BIIB)’s patent victory over the active ingredient in their competing multiple sclerosis treatments. Biogen popped 1.5 percent on the news.

Forward had previously won a number of legal cases in the U.S. to prevent patent-infringement on dimethyl fumarate (DMF) and recently demanded royalties from Biogen for its Tecfidera. Following the battles, Biogen made a $1.25 billion bid to acquire the patent in January, but Forward refused to accept, prompting Biogen to pursue legal action. The latest ruling could free Biogen to market Tecfidera without restriction.

In a related patent case, a district court found all four patents for Acorda Therapeutics Inc (NASDAQ: ACOR)’s Ampyra — another multiple sclerosis drug — invalid. Acorda fell 30 percent at the time.

Peer Alkermes Plc (NASDAQ: ALKS) also fell 5.3 percent on the market news. At time of publication, Biogen was up 1.25 percent, Forward down 19.7 percent and Acorda down 24.1 percent on the day.

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.